Fig. 2

COSIMO – study design and data collection. ^aDCE per telephone interview 4–12 weeks after starting rivaroxaban treatment. ^bPatients treated for at least 4 weeks of SOC anticoagulation therapy with LMWH or VKA therapy. ^cFor previous anticoagulation therapy. ^dFor rivaroxaban treatment. ^eIncluding anti-cancer medication. ^fHaemoglobin, haematocrit, white blood cells, platelets, electrolytes, C-reactive protein, serum creatinine, CrCl, liver enzymes and haemoccult test. ACTS, Anti-Clot Treatment Scale; CrCl, creatinine clearance; DCE, discrete choice experiment; DVT, deep vein thrombosis; FACIT, Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire; LMWH, low molecular weight heparin; PE, pulmonary embolism; SOC, standard of care; VKA, vitamin K antagonist